循环 miR-548a-3p 和 -20a 表达在恶性胸膜间皮瘤患者中的临床评估。
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
机构信息
Medical Biochemistry & Molecular Biology Department, Faculty of Medicine, Ain Shams University, Medical Ain Shams Research Center (MASRI). PO Box 11381, Abbassia, Cairo, Egypt.
Biomedical Research Department, Armed Forces College of Medicine, Cairo, Egypt.
出版信息
Biomark Med. 2018 Feb;12(2):129-139. doi: 10.2217/bmm-2017-0224. Epub 2018 Jan 17.
AIM
miRNAs may act as promising diagnostic and prognostic biomarkers of mesothelioma. This study integrates serum miR-548a-3p and miR-20a expression based on in silico data analysis followed by clinical validation in malignant mesothelioma patients (malignant pleural mesothelioma [MPM]).
PATIENTS & METHODS: Serum miR-548a-3p and miR-20a level was assessed in the serum of patients with MPM, chronic asbestos exposure and healthy volunteers by quantitative real-time PCR.
RESULTS
The expression of serum miR-548a-3p and miR-20a was positive in 91.6 and 96.7% MPM patients, respectively. Both miRNAs were able to segregate between cases and controls. The sensitivity of the combined chosen serum miRNAs reached 100% in the diagnosis of MPM.
CONCLUSION
The current work revealed that sera miR-548a-3p and miR-20a may serve as promising novel diagnostic tools for MPM.
目的
miRNA 可能作为间皮瘤有前途的诊断和预后生物标志物。本研究通过计算机数据分析整合血清 miR-548a-3p 和 miR-20a 的表达，随后在恶性间皮瘤患者（恶性胸膜间皮瘤 [MPM]）中进行临床验证。
患者与方法
采用实时定量 PCR 检测 MPM 患者、慢性石棉暴露者和健康志愿者血清中 miR-548a-3p 和 miR-20a 的水平。
结果
91.6%的 MPM 患者血清 miR-548a-3p 和 miR-20a 呈阳性表达。两种 miRNA 均能区分病例和对照组。联合选择的血清 miRNA 的灵敏度在 MPM 的诊断中达到 100%。
结论
本研究表明，血清 miR-548a-3p 和 miR-20a 可能成为 MPM 有前途的新型诊断工具。
Zotero 插件